AI assistant
Immunovant, Inc. — Director's Dealing 2022
Aug 19, 2022
31436_dirs_2022-08-19_5b884079-db2c-43e6-a991-4424b779b4b4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2022-08-17
Reporting Person: Hughes Douglas J. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-17 | Common Stock | A | 21059 | — | Acquired | 101232 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-17 | Stock Option (right to buy) | $4.99 | A | 31668 | Acquired | 2032-08-17 | Common Stock (31668.0) | Direct |
Footnotes
F1: Represents the number of shares underlying restricted stock units awards ("RSUs").
F2: The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F3: The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date.